Visualization and quantitation of peroxisomes using fluorescent nanocrystals: Treatment of rats and monkeys with fibrates and detection in the liver

Toxicological Sciences

Volumn 80, Issue 1, 2004, Pages 183-192

  Colton, Heidi M ^a   Falls, J G ^a   Ni, H ^a   Kwanyuen, P ^a   Creech, D ^a   McNeil, E ^a   Casey, W M ^a   Hamilton, G ^b   Cariello, N F ^a  

^a GLAXOSMITHKLINE   (United States)

^b Hepatotech Inc   (United States)

Author keywords

Fibrates; Immunofluorescence; Peroxisome proliferation; PMP70; Quantum Dots

Indexed keywords

CIPROFIBRATE; FIBRIC ACID DERIVATIVE; LIVER PROTEIN; MEMBRANE PROTEIN;

ANALYTIC METHOD; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL; CRYSTAL STRUCTURE; ELECTRON MICROSCOPY; ENZYME ACTIVITY; FLUORESCENCE ANALYSIS; IMAGE ANALYSIS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MONKEY; NONHUMAN; PEROXISOME; QUANTITATIVE ANALYSIS; QUANTUM YIELD; RAT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANIMALS; CLOFIBRATE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENT ANTIBODY TECHNIQUE; FROZEN SECTIONS; HUMANS; IMMUNOBLOTTING; LIVER; MACACA FASCICULARIS; MALE; MEMBRANE PROTEINS; MICROSCOPY, ELECTRON; PEROXISOMES; PROCETOFEN; QUANTUM DOTS; RATS; RATS, WISTAR; SPECIES SPECIFICITY;

MACACA FASCICULARIS;

EID: 3242781740     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/kfh144     Document Type: Article

References (35)

1. Ackers, J. T., Johnston, M. F., and Haasch, M. L. (2000). Immunodetection of hepatic peroxisomal PMP70 as an indicator of peroxisomal proliferation in the mummichog, Fundulus heteroclitus. Mar. Environ. Res. 50, 361-365.
2. Agard, D. A., Hiraoka, Y., Shaw, P., and Sedat, J. W. (1989). Fluorescence microscopy in three dimensions. Methods Cell Biol. 30, 353-377.
3. Beaufay, H., Jacques, P., Baudhuin, P., Sellinger, O. Z., Berthet, J., and DeDuve,C. (1964). Tissue fractionation studies: 18. Resolution of mitochondrial fractions from rat liver into three distinct populations of cytoplasmic particles by means of density equilibration in various gradients. Biochem. J. 92, 184-205.
4. Blaauboer, B. J., van Holsteijn, C. W., Bleumink, R., Mennes, W. C., van Pelt, F. N., Yap, S. H., van Pelt, J. F., van Iersel, A. A., Timmerman, A., and Schmid, B. P. (1990). The effect of beclobric acid and clofibric acid on peroxisomal beta-oxidation and peroxisome proliferation in primary cultures of rat, monkey, and human hepatocytes. Biochem. Pharmacol. 40, 521-528.
5. Choudbury, A. I., Chahal, S., Bell, A. R., Tomlinson, S. R., Roberts, R. A., Salter, A. M., and Bell, D. R. (2000). Species differences in peroxisome proliferation: Mechanisms and relevance. Mutat. Res. 448, 201-212.
6. Corton, J. C., Anderson, S. P., and Stauber, A. (2000). Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu. Rev. Pharmacol. Toxicol. 40, 491-518.
7. Dansen, T. B., Wirtz, K. W. A., Wanders, R. J. A., and Pap, E. H. W. (2000). Peroxisomes in human fibroblasts have a basic pH. Nat. Cell Biol. 2, 51-53.
8. Dunnett, C. W. (1955). A multiple-comparisons procedure of comparing several treatments with a control. J. Amer. Stat. Assoc. 50, 1096-1121.
9. Eacho, P. I., Foxworthy, P. S., Johnson, W. D., Hoover, D. M., and White, S. L. (1986). Hepatic peroxisomal changes induced by a tetrazole-substituted alkoxyacetophenone in rats and comparison with other species. Toxicol. Appl. Pharmacol. 3, 430-437.
10. Escher, P., and Wahli, W. (2000). Peroxisome proliferator-activated receptors: Insight into multiple cellular functions. Mutat.. Res. 448, 121-138.
11. Fahimi, H. D., and Baumgart, E. (1999). Current cytochemical techniques for the investigation of peroxisomes: A review. J. Histochem. Cytochem. 47, 1219-1232.
12. Ferry, N., Bernard, N., Pozet, N., Gardes, E., Cuisinaud, G., Labeeuw, M., Zech, P. Y., and Sassard, J. (1989). The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate. Brit. J. Clin. Pharmacol. 28, 675-681.
13. Foxworthy, P. S., White, S. L., Hoover, D. M., and Eacho, P. I. (1990). Effect of ciprofibrate, bezafibrate, and LY171883 on peroxisomal beta-oxidation in cultured rat, dog, and rhesus monkey hepatocytes. Toxicol. Appl. Pharmacol. 104, 386-394.
14. Gonzalez, F. J. (2002). The peroxisome proliferator-activated receptor α (PPAR-α): Role in hepatocarcinogenesis. Mol. Cell Endocrinol. 193, 71-79.
15. Graham, M. J., Wilson, S. A., Winham, M. A., Spencer, A. J., Rees, J. A., Old, S. L., and Bonner, F. W. (1994). Lack of peroxisome proliferation in marmoset liver following treatment with ciprofibrate for 3 years. Fundam. Appl. Toxicol. 22, 58-64.
16. Hawkins, J. M., Jones, W. E., Bonner, F. W., and Gibson, G. G. (1987). The effect of peroxisome proliferators on microsomal, peroxisomal, and mitochondrial enzyme activities in the liver and kidney. Drug Metab. Rev. 18, 441-515.
17. Hiltunen, J. K., and Qin, Y. (2000). Beta-oxidation - strategies for the metabolism of a wide variety of acyl-CoA esters. Biochim. Biophys. Acta 1484, 117-128.
18. Hoivik, D., Qualls, C. W., Jr., Mirabile, R. C., Cariello, N. F., Colton, H. M., Anderson, S. P., Santosteffano, M. J., Ott-Morgan, R. J., Dahl, R. R., Brown, A. R., Zhao, Z. Z., Mudd, P. M., Oliver, W. B., Brown, R. M., and Miller, R. T. (2003). Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence for cellular proliferation and oxidative stress in cynomolgus monkeys. Carcinogenesis (in press).
19. Hoivik, D. J., Qualls, C. W. J., Mirabile, R. C., Cariello, N. F., Colton, H. M., Anderson, S. P., Samosteffano, M. J., Ott-Morgan, R. J., Dahl, R. R., Brown, A. R., Zhao, Z. Z., Mudd, P. M., Oliver, W. B., Brown, R. M., and Miller, R. T. (2004). Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence for cellular proliferation and oxidative stress in cynomolgus monkeys. Carcinogenesis (in press).
20. Hsu, M. H., Savas, U., Griffin, K. J., and Johnson, E. F. (2001). Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells. J. Biol. Chem. 276, 27950-27958.
21. Imanaka, T., Aihara, K., Takano, T., Yamashita, A., Sato, R., Suzuki, Y., Yokota, S., and Osumi, T. (1999). Characterization of the 70-kDa peroxisomal membrane protein, an ATP binding cassette transporter. J. Biol. Chem. 274, 11968-11976.
22. Kemp, S., Wei, H. M., Lu, L. F., Braiterman, L. T., McGuinness, M. C., Moser, A. B., Watkins, P. A., and Smith, K. D. (1998). Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy. Nat. Med. 4, 1261-1268.
23. Klaunig, J. E., Babich, M. A., Baetcke, K. P., Cook, J. C., Corton, J. C., David, R. M., DeLuca, J. G., Lai, D. Y., McKee, R. H., Peters, J. M., Roberts, R. A., and Fenner-Crisp, P. A. (2003). PPAR alpha agonist-induced rodent tumors: Modes of action and human relevance. Crit. Rev. Toxicol. 33, 655-780.
24. Lawrence, J. W., Li, Y., Chen, S., DeLuca, J. G., Berger, J. P., Umbenhauer, D. R., Moller, D. E., and Zhou, G. (2001). Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR)-alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression. J. Biol. Chem. 276, 31521-31527.
25. Makowska, J. M., Gibson, G. G., and Bonner, F. W. (1992). Species differences in ciprofibrate induction of hepatic cytochrome P450 4A1 and peroxisome proliferation. J. Biochem. Toxicol. 7, 183-191.
26. Masters, C., and Crane, C. (1995). The Peroxisome: A Vital Organelle. Cambridge University Press, Cambridge, U.K.
27. Miller, D. B., and Spence, J. D. (1998). Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin. Pharmacokinet. 34, 155-162.
28. Novikoff, A. B., Novikoff, P. M., Davis, C., and Quintana, N. (1973). Studies on microperoxisomes: V. Are microperoxisomes ubiquitous in mammalian cells? J. Histochem. Cytochem. 21, 737-755.
29. PDR (2004). LOFIBRA™ (Gate) Fenofibrate capsules (micronized). In Physicians' Desk Reference Electronic Library. Thomson MICROMEDEX.
30. Peters, J. M., Cattley, R. C., and Gonzalez, F. J. (1997). Role of PPAR-α in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator WY-14,643. Carcinogenesis 18, 2029-2033.
31. Reddy, J. K., Lalwani, N. D., Qureshi, S. A., Reddy, M. K., and Moehle, C. M. (1984). Induction of hepatic peroxisome proliferation in nonrodent species, including primates. Am. J. Pathol. 114, 171-183.
32. Schrader, M., Reuber, B. E., Morrell, J. C., Jimenezsanchez, G., Obie, C., Stroh, T. A., Valle, D., Schroer, T. A., and Gould, S. J. (1998). Expression of Pex11-beta mediates peroxisome proliferation in the absence of extracellular stimuli. J. Biol. Chem. 273, 29607-29614.
33. Tanaka, A. R., Tanabe, K., Morita, M., Kurisu, M., Kasiwayama, Y., Matsuo, M., Kioka, N., Amachi, T., Imanaka, T., and Ueda, K. (2002). ATP binding/hydrolysis by the physphorylation of peroxisomal ATP-binding cassette proteins PMP70 (ABCD3) and adrenoleukodystrophy protein (ABCD1). J. Biol. Chem. 277, 40142-40147.
34. Titorenko, V. L, and Rachubinski, R. A. (2001). The life cycle of the peroxisome. Nat. Rev. Mol. Cell. Biol. 2, 357-368.
35. Zammit, V. A. (2000). Carnitine acyltransferases: Functional significance of subcellular distribution and membrane topology. Cell Biochem. Biophys. 32, 63-72.